FR2523446A1 - Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee - Google Patents
Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee Download PDFInfo
- Publication number
- FR2523446A1 FR2523446A1 FR8204672A FR8204672A FR2523446A1 FR 2523446 A1 FR2523446 A1 FR 2523446A1 FR 8204672 A FR8204672 A FR 8204672A FR 8204672 A FR8204672 A FR 8204672A FR 2523446 A1 FR2523446 A1 FR 2523446A1
- Authority
- FR
- France
- Prior art keywords
- konjak
- surfactant
- mannans
- per unit
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002752 Konjac Polymers 0.000 title claims abstract description 32
- 235000010485 konjac Nutrition 0.000 title claims abstract description 31
- 229920000057 Mannan Polymers 0.000 title claims abstract description 16
- 239000004094 surface-active agent Substances 0.000 title claims abstract description 9
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000000843 powder Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract description 10
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 15
- 229960000905 indomethacin Drugs 0.000 claims description 13
- 239000002563 ionic surfactant Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 abstract description 3
- 241001278826 Amorphophallus Species 0.000 abstract description 2
- 229940124584 antitussives Drugs 0.000 abstract description 2
- 239000002876 beta blocker Substances 0.000 abstract description 2
- 229940097320 beta blocking agent Drugs 0.000 abstract description 2
- 239000002532 enzyme inhibitor Substances 0.000 abstract description 2
- 235000013312 flour Nutrition 0.000 abstract description 2
- 238000000265 homogenisation Methods 0.000 abstract description 2
- 239000003076 neurotropic agent Substances 0.000 abstract description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 abstract 1
- 230000000954 anitussive effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 1
- 229940125532 enzyme inhibitor Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 239000002132 β-lactam antibiotic Substances 0.000 abstract 1
- 229940124586 β-lactam antibiotics Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 4
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 4
- 235000012141 vanillin Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229960004126 codeine Drugs 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960004559 theobromine Drugs 0.000 description 3
- INAXVXBDKKUCGI-UHFFFAOYSA-N 4-hydroxy-2,5-dimethylfuran-3-one Chemical compound CC1OC(C)=C(O)C1=O INAXVXBDKKUCGI-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- WRCHFMBCVFFYEQ-UHFFFAOYSA-N clofedanol Chemical compound C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 WRCHFMBCVFFYEQ-UHFFFAOYSA-N 0.000 description 1
- 229960004472 clofedanol Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8204672A FR2523446A1 (fr) | 1982-03-19 | 1982-03-19 | Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8204672A FR2523446A1 (fr) | 1982-03-19 | 1982-03-19 | Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2523446A1 true FR2523446A1 (fr) | 1983-09-23 |
| FR2523446B3 FR2523446B3 (enrdf_load_stackoverflow) | 1985-01-25 |
Family
ID=9272168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8204672A Granted FR2523446A1 (fr) | 1982-03-19 | 1982-03-19 | Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2523446A1 (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2585246A1 (fr) * | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
| WO1995025516A1 (en) * | 1994-03-24 | 1995-09-28 | Smithkline Beecham Plc | Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant |
| US5486364A (en) * | 1992-12-30 | 1996-01-23 | Fmc Corporation | Readily available konjac glucomannan as a sustained release excipient |
| EP2826464A1 (en) * | 2013-07-19 | 2015-01-21 | Shimizu Chemical Corporation | Sustained release solid dosage preparations |
-
1982
- 1982-03-19 FR FR8204672A patent/FR2523446A1/fr active Granted
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2585246A1 (fr) * | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
| EP0214735A1 (en) * | 1985-07-26 | 1987-03-18 | Euroceltique S.A. | Controlled release pharmaceutical composition |
| US5486364A (en) * | 1992-12-30 | 1996-01-23 | Fmc Corporation | Readily available konjac glucomannan as a sustained release excipient |
| EP0676967A4 (en) * | 1992-12-30 | 1996-10-02 | Fmc Corp | RELEASED, EXTENDED, EASY TO PRODUCE EXCIPIENT, BASED ON KONJAC GLUCOMANNANE. |
| WO1995025516A1 (en) * | 1994-03-24 | 1995-09-28 | Smithkline Beecham Plc | Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant |
| EP2826464A1 (en) * | 2013-07-19 | 2015-01-21 | Shimizu Chemical Corporation | Sustained release solid dosage preparations |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2523446B3 (enrdf_load_stackoverflow) | 1985-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1005691A4 (fr) | Composition pharmaceutique a base de ranitidine et son procede de preparation. | |
| CA1254143A (en) | Pharmaceutical preparation with a content of ibuprofen, and process for its preparation | |
| EP0233853B1 (fr) | Couples effervescents, compositions effervescentes d'antagonistes H2 de l'histamine les contenant et leur préparation | |
| EP2349217B1 (fr) | Granulé d'acide gamma-hydroxybutyrique | |
| SU1151193A3 (ru) | Способ получени перорального препарата дипиридамола | |
| FR2542735A1 (fr) | Resinate d'un acide carboxylique substitue, procedes pour sa preparation, son utilisation et compositions pharmaceutiques le contenant | |
| BE1015217A5 (enrdf_load_stackoverflow) | ||
| EP0673245B1 (fr) | Composition pharmaceutique effervescente contenant de l'ibuprofene et son procede de preparation | |
| FR2471786A1 (fr) | Composition pharmaceutique seche a liberation lente contenant un excipient sec et procedes pour preparer cette composition et cet excipient | |
| FR2585570A1 (fr) | Procede de preparation d'une forme granulaire a liberation retardee d'un principe actif et forme granulaire obtenue | |
| JPS6147807B2 (enrdf_load_stackoverflow) | ||
| EP1178809A1 (fr) | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel | |
| BE1000496A7 (fr) | Procede pour la production de preparations pharmaceutiques ayant une haute capacite de fixation de l'acide gastrique, exercant un effet retard et ayant une biodisponibilite accrue. | |
| CZ369292A3 (en) | Per-orally applicable form of a medicament for treating central states of dopamine insufficiency | |
| FR2726469A1 (fr) | Composition pharmaceutique pour l'administration orale de flavonoides | |
| JP2008546782A (ja) | 水溶性鎮痛剤およびその製造方法 | |
| FR2774910A1 (fr) | Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques | |
| FR2904774A1 (fr) | Composition pharmaceutique solide contenant une combinaison d'un agent regulateur de la motilite intestinale et d'un antiflatulent. | |
| FR2540727A1 (fr) | Nouvelle preparation retard contenant de la n''-cyano-n-4-pyridyl-n'-1,2,2-trimethylpropylguanidine, utile notamment dans le traitement de l'hypertension | |
| FR2661610A1 (fr) | Nouvelle forme lyophilisee de la diosmine et sa preparation. | |
| FR2563108A1 (fr) | Composition pharmaceutique antiacide et suspension aqueuse la contenant | |
| FR2523446A1 (fr) | Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee | |
| FR2531339A1 (fr) | Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee | |
| FR2499407A1 (fr) | Composition pharmaceutique et son application therapeutique pour le traitement des maladies de la cavite buccale | |
| FR2489146A1 (fr) | Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide |